









Markets
/
Stocks
/
nasdaq-cers
/

Cerus Corp

CERS

1.710USD

+0.300+21.28%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

327.62MMarket Cap

LossP/E TTM



Cerus Corp

1.710

+0.300+21.28%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cerus Corp

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cerus Corp's Score

Industry at a Glance

Industry Ranking

68 / 209

Overall Ranking

156 / 4614

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+230.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cerus Corp Highlights

StrengthsRisks

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Undervalued

The company’s latest PE is -20.32, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 139.12M shares, decreasing 7.28% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 19.21M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.28, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 52.70M, representing a year-over-year increase of 4.03%, while its net profit experienced a year-over-year increase of 99.35%.

Score

Industry at a Glance

Previous score

7.28

Change



Financials

5.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.27

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.29

Key Metrics

Free cash flow

No Data

Cerus Corp's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.27, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -20.32, which is -77.85% below the recent high of -4.50 and 0.00% above the recent low of -20.32.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/209

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.50, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Cerus Corp is 5.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+230.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Cerus Corp

CERS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 8.78, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 1.83 and the support level at 1.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.11

Change

2.67

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Buy

RSI(14)

62.394

Neutral

STOCH(KDJ)(9,3,3)

60.767

Buy

ATR(14)

0.095

High Vlolatility

CCI(14)

156.264

Buy

Williams %R

4.348

Overbought

TRIX(12,20)

-0.138

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.508

Buy

MA10

1.490

Buy

MA20

1.528

Buy

MA50

1.465

Buy

MA100

1.406

Buy

MA200

1.443

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 72.57%, representing a quarter-over-quarter decrease of 7.63%. The largest institutional shareholder is Catherine Wood, holding a total of 19.21M shares, representing 10.02% of shares outstanding, with 10.60% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

19.21M

-7.01%

BlackRock Institutional Trust Company, N.A.

15.43M

+19.30%

Baker Bros. Advisors LP

12.88M

-33.42%

The Vanguard Group, Inc.

Star Investors

10.72M

+1.59%

Wasatch Global Investors Inc

Star Investors

8.53M

+2.57%

Amova Asset Management Co., Ltd.

6.07M

-1.96%

Geode Capital Management, L.L.C.

4.35M

-4.25%

BlackRock Financial Management, Inc.

4.16M

+242.32%

Senvest Management, LLC

4.01M

-9.08%

State Street Investment Management (US)

3.83M

+0.85%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.97, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.57. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.